Cardinal Health, Inc. (CAH) fair value analysis
S&P 500 · Updated 2026-10-19
CAH price how computed
Forward Fair Value verdict
OvervaluedCAH is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $237.57
- Sector
- Healthcare
- 12-month range
- $161.89–$254.06
- Market cap
- $55B
- From 52-week high
- -6.5%
- Shares outstanding
- 232M
- Rank in Healthcare by discount to fair value
- #75 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Cardinal Health, Inc. is a healthcare services company that distributes pharmaceutical products, medical supplies, and equipment to hospitals, pharmacies, and healthcare providers across the United States and internationally. The company also operates a global manufacturing segment that produces generic drugs and other pharmaceutical products for healthcare systems worldwide.
CAH currently ranks #75 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $55B
- P/E (trailing)
- 21x
- Revenue (TTM)
- $254B
- Net margin
- 0.7%
- EPS (TTM)
- $11.26
- Gross margin
- 4.3%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 5.6%
- Shares outstanding
- 232M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 78 · overbought
- 50-day average
- $234.40
- 200-day average
- $219.87
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $2.05 per share (4 payments)
- Yield on last price
- 0.86%
- Consecutive years of increases
- 1
- Last ex-dividend date
- 2026-10-01
- Last payment date
- 2026-10-15
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+20.2%)
2026-03 ▲ beat (+13.6%)
2025-12 ▲ beat (+11.0%)
2025-09 ▲ beat (+17.5%)
2025-06 ▲ beat (+2.5%)
2025-03 ▲ beat (+9.3%)
2024-12 ▲ beat (+9.7%)
2024-09 ▲ beat (+16.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 3 hold · 0 sell (17 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $271
- Target vs last price
- +14.1%
What our data shows for CAH
- Our model validated 17 trailing price-to-earnings windows for CAH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $161.89–$254.06.
- The 14-day relative strength index sits at an overbought 78.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CAH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CAH news
TickrTrends' derived news-sentiment signal for CAH is currently leaning positive, computed from recent coverage.
- CAH Maintained by UBS -- Price Target Raised to $295 (gurufocus.com, 2026-10-16)
TickrTrends take: UBS raised its price target for CAH to 295, which represents analyst confidence in the company's fundamental prospects within the healthcare sector. However, TickrTrends currently derives an overvalued verdict for CAH, suggesting that the stock's current market price may already reflect or exceed the value implied by its financial metrics. Investors focused on valuation should monitor whether CAH's market performance converges with or diverges from both the analyst target and TickrTrends' assessment in the coming periods. - Cardinal Health Inc (CAH) Shares Surge 3.4% -- What GF Score of 78 Tells Investors (gurufocus.com, 2026-10-14)
TickrTrends take: Cardinal Health shares recently moved higher, and the stock carries a GF Score of 78, which suggests reasonable fundamental quality. However, TickrTrends currently derives an Overvalued verdict for CAH in the Healthcare sector, indicating that the recent price movement may not align with valuation metrics at current levels. Investors focused on valuation should monitor whether the company's fundamentals justify closing any gap between its current price and fair value estimates. - Is Cardinal Health Inc (CAH) Overvalued After 3.4% Rally? GF Value Says Overvalued (gurufocus.com, 2026-10-01)
TickrTrends take: Cardinal Health trades in a sector where valuation assessments can shift with earnings performance and operational efficiency metrics. TickrTrends currently marks the stock as fairly valued, which contrasts with some analysts' views that the recent rally has pushed it toward overvaluation territory. A reader focused on valuation should monitor whether Cardinal Health's fundamentals—such as margins, cash flow generation, and segment profitability—can justify any price gains, since healthcare companies often see valuation reassessments when operational trends change.
More CAH news
- Cardinal Health: I'm Still Buying After Checking The Numbers (NYSE:CAH) (seekingalpha.com, 2026-09-30)
- GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over? (insidermonkey.com, 2026-09-23)
What people are saying
Follow the CAH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for CAH show a shift in momentum this week, with the RSI zone moving from neutral territory into overbought conditions. The stock maintains an overvalued valuation verdict according to current assessments. This combination of overbought momentum and overvalued pricing may warrant attention from investors monitoring the healthcare sector.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — CAH's valuation metrics have shifted negatively this week. The sector discount rank declined from #83 to #88, indicating the stock has become less attractively priced relative to other healthcare companies, while the valuation verdict moved from Fairly valued to Overvalued, suggesting the current price has moved above levels supported by fundamental metrics.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — CAH's valuation metrics improved this week as its sector discount rank moved from 95th to 84th place among Healthcare stocks. The stock's valuation verdict shifted from Overvalued to Fairly valued, reflecting a more balanced pricing relative to the sector.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CAH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CAH is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is CAH's TickrTrends verdict?
CAH's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does CAH compare to other Healthcare stocks?
CAH ranks #75 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is CAH overbought or oversold?
CAH's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does CAH pay a dividend?
Yes. CAH paid $2.05 per share over the last twelve months (4 payments), a 0.86% yield on TickrTrends' last price, and has raised the annual total for 1 consecutive year. The last ex-dividend date was 2026-10-01.
When does CAH report earnings next?
CAH's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does CAH usually beat earnings estimates?
Over its last 8 reported quarters CAH beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CAH?
Of 17 analysts covering CAH, 14 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $271 (+14.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
CAH vs ABBV · CAH vs ACAD · CAH vs BIIB · CAH vs BIOA · CAH vs BMY